Harnessing targeted IL-2 to reduce immunopathology and enhance immunity against respiratory virus infection

利用靶向 IL-2 来减少免疫病理并增强对呼吸道病毒感染的免疫力

基本信息

批准号：
10680533
负责人：
Tara Marlene Strutt
金额：
$ 38万
依托单位：
UNIVERSITY OF CENTRAL FLORIDA
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-22 至 2026-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10680533
关键词：
Acute Respiratory Distress Syndrome Adjuvant Advanced Development Affinity Animals Antibody Formation Antiviral Agents B-Lymphocytes CD8-Positive T-Lymphocytes Cells Clinical Combined Modality Therapy Development Disease Dose FOXP3 gene Generations Goals Hospitalization IL2RA gene Immune Immunity Immunoglobulin Class Switching Immunologic Memory Individual Infection Inflammation Inflammatory Inflammatory Response Influenza Influenza A virus Interleukin 2 Receptor Interleukin-2 Intervention Knowledge Lung Lymphocyte Lymphoid Cell Memory Modeling Mus Names Natural Killer Cells Oseltamivir Outcome Pathway interactions Plasma Cells Population Predisposition Public Health Regulation Regulatory T-Lymphocyte Reporting Role Shapes Signal Transduction Structure of germinal center of lymph node T-Lymphocyte Therapeutic Therapeutic Intervention Tissues Treatment outcome Vaccination Viral Viral Respiratory Tract Infection Virus Virus Diseases antiviral immunity cytokine release syndrome effector T cell global health immunopathology improved improved outcome influenza infection innovation inorganic phosphate insight memory CD4 T lymphocyte mortality risk novel pre-clinical prevent pulmonary function respiratory infection virus response tissue repair ventilation

项目摘要

Influenza A virus (IAV) remains a global health concern despite annual vaccination efforts. Clinical interventions able to prevent the immunopathology and `cytokine storm' associated with severe IAV infection are urgently needed, especially approaches that can be initiated at later stages of infection. The knowledge gained from the proposed studies will facilitate the development of a novel application of an IL-2-based therapeutic approach to treat severe respiratory viral infection, as well as advance its potential use as an adjuvant to boost universal, IAV-specific immunity following vaccination.

尽管每年都进行疫苗接种工作，甲型流感病毒 (IAV) 仍然是全球健康问题。临床干预迫切需要能够预防与严重 IAV 感染相关的免疫病理学和“细胞因子风暴” 需要，特别是可以在感染后期启动的方法。从中获得的知识拟议的研究将促进基于 IL-2 的治疗方法的新应用的开发治疗严重呼吸道病毒感染，并推进其作为佐剂的潜在用途，以促进普遍、接种疫苗后产生 IAV 特异性免疫力。

项目成果

期刊论文数量（1）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Intermediate Levels of Pre-Existing Protective Antibody Allow Priming of Protective T Cell Immunity against Influenza.

预先存在的中等水平的保护性抗体可启动针对流感的保护性 T 细胞免疫。

DOI：
发表时间：
2023-03-01
期刊：
影响因子：
0
作者：
Ng, Terry;Flores;Mansoor, Mishfak A M;Arvelo, Andrea C;Dhume, Kunal;Prokop, Emily;McKinstry, K Kai;Strutt, Tara M
通讯作者：
Strutt, Tara M